The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture

Journal of Proteomics

Volumn 106, Issue , 2014, Pages 61-73

  Jorge, Inmaculada ^a,b   Burillo, Elena ^a,c   Mesa, Raquel ^a,b   Baila Rueda, Lucía ^c   Moreno, Margoth ^a   Trevisan Herraz, Marco ^a,b   Silla Castro, Juan Carlos ^a,b   Camafeita, Emilio ^a,b   Ortega Muñoz, Mariano ^a   Bonzon Kulichenko, Elena ^a,b   Calvo, Isabel ^c   Cenarro, Ana ^c   Civeira, Fernando ^c   Vázquez, Jesús ^a,b  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Atheroma plaque; HDL; Proteomics; Stable isotopic labeling; System biology

Indexed keywords

ACTIN; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; FIBRINOGEN; FIBRONECTIN; HAPTOGLOBIN; HEMOGLOBIN BETA CHAIN; HEMOPEXIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN LAMBDA CHAIN; LIPOCORTIN 1; PROTEOME; PROTHROMBIN; SERUM AMYLOID A; STABLE ISOTOPE; CHOLESTEROL; PEPTIDE; TRYPSIN;

ALGORITHM; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; PROTEOMICS; QUANTITATIVE ANALYSIS; SYSTEMS BIOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; AFFINITY CHROMATOGRAPHY; CHEMISTRY; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY;

ALGORITHMS; APOLIPOPROTEINS; CHOLESTEROL; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; ISOELECTRIC FOCUSING; LIPOPROTEINS, HDL; MALE; PEPTIDES; PLAQUE, ATHEROSCLEROTIC; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY; TRYPSIN;

EID: 84899893659     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.04.010     Document Type: Article

References (45)

1. Assmann G., Cullen P., Schulte H. The Munster heart study (PROCAM). Results of follow-up at 8years. Eur Heart J 1998, 19(Suppl. A):A2-A11.
2. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977, 62:707-714.
3. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
4. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
5. Burillo E., Andres E.M., Mateo-Gallego R., Fiddyment S., Jarauta E., Cenarro A., et al. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. Heart 2010, 96:1345-1351.
6. Seo S.M., Choo E.H., Koh Y.S., Park M.W., Shin D.I., Choi Y.S., et al. Catholic University of Korea PrCIRi. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 2011, 97:1943-1950.
7. Brewer H.B. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 2007, 9:486-492.
8. Gordon S.M., Deng J., Lu L.J., Davidson W.S. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010, 9:5239-5249.
9. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
10. Rau J.C., Beaulieu L.M., Huntington J.A., Church F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007, 5(Suppl. 1):102-115.
11. Heinecke J.W. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J Clin Lipidol 2010, 4:371-375.
12. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol 2012, 10:410-421.
13. Cheung M.C., Segrest J.P., Albers J.J., Cone J.T., Brouillette C.G., Chung B.H., et al. Characterization of high density lipoprotein subspecies: structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography. J Lipid Res 1987, 28:913-929.
14. Bonzon-Kulichenko E., Perez-Hernandez D., Nunez E., Martinez-Acedo P., Navarro P., Trevisan-Herraz M., et al. A robust method for quantitative high-throughput analysis of proteomes by 18O labeling. Mol Cell Proteomics 2011, 10. [M110 003335].
15. Burillo E., Vazquez J., Jorge I. Quantitative proteomics analysis of high-density lipoproteins by stable (18)O-isotope labeling. Methods Mol Biol 2013, 1000:139-156.
16. Lopez-Ferrer D., Ramos-Fernandez A., Martinez-Bartolome S., Garcia-Ruiz P., Vazquez J. Quantitative proteomics using 16O/18O labeling and linear ion trap mass spectrometry. Proteomics 2006, 6(Suppl. 1):S4-S11.
17. Ramos-Fernandez A., Lopez-Ferrer D., Vazquez J. Improved method for differential expression proteomics using trypsin-catalyzed 18O labeling with a correction for labeling efficiency. Mol Cell Proteomics 2007, 6:1274-1286.
18. Jorge I., Navarro P., Martinez-Acedo P., Nunez E., Serrano H., Alfranca A., et al. Statistical model to analyze quantitative proteomics data obtained by 18O/16O labeling and linear ion trap mass spectrometry: application to the study of vascular endothelial growth factor-induced angiogenesis in endothelial cells. Mol Cell Proteomics 2009, 8:1130-1149.
19. Lopez-Ferrer D., Martinez-Bartolome S., Villar M., Campillos M., Martin-Maroto F., Vazquez J. Statistical model for large-scale peptide identification in databases from tandem mass spectra using SEQUEST. Anal Chem 2004, 76:6853-6860.
20. Martinez-Bartolome S., Navarro P., Martin-Maroto F., Lopez-Ferrer D., Ramos-Fernandez A., Villar M., et al. Properties of average score distributions of SEQUEST: the probability ratio method. Mol Cell Proteomics 2008, 7:1135-1145.
21. Navarro P., Vazquez J. A refined method to calculate false discovery rates for peptide identification using decoy databases. J Proteome Res 2009, 8:1792-1796.
22. Navarro P., Trevisan-Herraz M., Bonzon-Kulichenko E., Núñez E., Martínez-Acedo P., Pérez-Hernández D., et al. General statistical framework for quantitative proteomics by stable isotope labeling. J Proteome Res 2014, 13:1234-1247.
23. Alwaili K., Bailey D., Awan Z., Bailey S.D., Ruel I., Hafiane A., et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821, 2012:405-415.
24. Mange A., Goux A., Badiou S., Patrier L., Canaud B., Maudelonde T., et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One 2012, 7:e34107.
25. Heller M., Stalder D., Schlappritzi E., Hayn G., Matter U., Haeberli A. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 2005, 5:2619-2630.
26. Green P.S., Vaisar T., Pennathur S., Kulstad J.J., Moore A.B., Marcovina S., et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118:1259-1267.
27. Mazur M.T., Cardasis H.L., Spellman D.S., Liaw A., Yates N.A., Hendrickson R.C. Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. Proc Natl Acad Sci U S A 2010, 107:7728-7733.
28. Vaisar T., Mayer P., Nilsson E., Zhao X.Q., Knopp R., Prazen B.J. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010, 411:972-979.
29. Moore D., McNeal C., Macfarlane R. Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease. Biochem Biophys Res Commun 2011, 404:1034-1038.
30. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
31. Rezaee F., Casetta B., Levels J.H., Speijer D., Meijers J.C. Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6:721-730.
32. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34:1345-1353.
33. Asztalos B.F., Tani M., Schaefer E.J. Metabolic and functional relevance of hdl subspecies. Curr Opin Lipidol 2011, 22:176-185.
34. Tölle M., Huang T., Schuchardt M., Jankowski V., Prüfer N., Jankowski J., et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 2012, 94:154-162.
35. Duka A., Fotakis P., Georgiadou D., Kateifides A., Tzavlaki K., von Eckardstein L., et al. ApoA-IV promotes the biogenesis of ApoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. J Lipid Res 2013, 54:107-115.
36. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990, 265:4266-4272.
37. Tian L., Xu Y., Fu M., Jia L., Yang Y. Influence of apolipoprotein CII concentrations on hdl subclass distribution. J Atheroscler Thromb 2009, 16:611-620.
38. Suzuki M., Becker L., Pritchard D.K., Gharib S.A., Wijsman E.M., Bammler T.K., et al. Cholesterol accumulation regulates expression of macrophage proteins implicated in proteolysis and complement activation. Arterioscler Thromb Vasc Biol 2012, 32:2910-2918.
39. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
40. Farrell D.H. Γ' fibrinogen as a novel marker of thrombotic disease. Clin Chem Lab Med 2012, 50:1903-1909.
41. Afshari A., Wetterslev J., Brok J., Moller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007, 335:1248-1251.
42. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
43. Viiri L.E., Full L.E., Navin T.J., Begum S., Didangelos A., Astola N., et al. Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol 2013, 54:65-72.
44. Mendez A.J., Goldberg R.B., Arnold P.I., Schultz D.R. Acquire HDL deficiency associated with apolipoprotein A-I reactive monoclonal immunoglobulins. Arterioscler Thromb Vasc Biol 2002, 22.
45. Norata G.D., Pirillo A., Ammirati E., Catapano A.L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012, 220:11-21.